GCG and type 2 diabetes mellitus: Despite that lacking secretion or faster clearance of incretin are not pathogenic factors in diabetes, GLP-1 has become a molecular target for therapeutics of type 2 diabetes mellitus (type 2 DM) since its insulinotropic activity is still active in these patients, but not GIP [1, 2].